Evidence map›Paper›PMID 40442554›Full record

ArticlePituitary2025

The diagnosis of GH deficiency in adult β-thalassemic patients: are two different stimulation tests necessary to improve specificity?

Daniele Sola, Mirna Solange Barrio Lower Daniele, Leila Danesi, Emanuela D'Angelo, Nadia Mirra, Giovanna Graziadei, Elena Cassinerio, Riccardo Pasquali, Massimo Scacchi

Abstract read
In one paragraph

Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniele SolaIRCCS Istituto Auxologico Italiano, Laboratory of Metabolic Research, Ospedale S. Giuseppe, Piancavallo, Oggebbio (VB), 2884, Italy. d.sola@auxologico.it.ORCID http://orcid.org/0000-0001-7863-8192
Mirna Solange Barrio Lower DanieleIRCCS Istituto Auxologico Italiano, Laboratory of Metabolic Research, Ospedale S. Giuseppe, Piancavallo, Oggebbio (VB), 2884, Italy.
Leila DanesiSC Metabolic Medicine Department, Fondazione IRCCS Cà Granda Maggiore Policlinico, Milan, Italy.
Emanuela D'AngeloSC Pediatric Emergency Department, Fondazione IRCCS Cà Granda Maggiore Policlinico, Milan, Italy.
Nadia MirraSC Pediatric Emergency Department, Fondazione IRCCS Cà Granda Maggiore Policlinico, Milan, Italy.
Giovanna GraziadeiSC Metabolic Medicine Department, Fondazione IRCCS Cà Granda Maggiore Policlinico, Milan, Italy.
Elena CassinerioSC Metabolic Medicine Department, Fondazione IRCCS Cà Granda Maggiore Policlinico, Milan, Italy.
Riccardo PasqualiOncological Endocrinology, Istituto Europeo di Oncologia (IEO), Milan, Italy.
Massimo ScacchiIRCCS Istituto Auxologico Italiano, Laboratory of Metabolic Research, Ospedale S. Giuseppe, Piancavallo, Oggebbio (VB), 2884, Italy.

Funding

Italian Ministry of Health - Ricerca Finalizzata 1519507
6 · The paper itself

Abstract

purposeβ-thalassemia major (βTM) frequently leads to endocrinological complications of chronic transfusion-induced iron overload, including growth hormone deficiency (GHD). With contrasting data on GHD in adult βTM populations, our study aimed to reevaluate the diagnosis of GHD using multiple tests and its progression over time.

methodsTwo experimental studies were conducted in adult βTM patients to assess GH secretory status. The first study reevaluated GH secretion after two years using a GHRH plus arginine test performed initially and during follow-up. The second study applied a glucagon stimulation test to those initially diagnosed with severe GHD, comparing the results with those of a GHRH plus arginine test.

resultsThe first study involved 80 patients: 67 patients had normal GH secretion at the first test, confirmed in 57 of them. Of the 13 initially diagnosed with GHD, only 3 were confirmed at the second test. The second study included 91 patients: 18 of the initially identified as having severe GHD, were tested with another challenge, but only 6 confirmed severe GHD, suggesting a possible risk of overdiagnosis in initial evaluations.

conclusionsThe marked variability in GHD diagnoses among adult patients with βTM highlights the need for multiple diagnostic tests to improve accuracy and avoid unnecessary interventions. Our findings highlight the importance of reassessing GH secretory reserves with multiple tests at multiple time points, supporting a cautious approach to hormone replacement therapy, suggesting to start it only when clearly indicated.

Indexed as

beta-ThalassemiaHuman Growth HormoneAdultArginineFemaleGlucagonGrowth Hormone-Releasing HormoneHumansMaleMiddle AgedYoung AdultArginineGlucagonGrowth Hormone-Releasing HormoneHuman Growth HormoneGHRH plus arginine testGlucagon testGrowth hormone (GH)Growth hormone secretion defect (GHD)Thalassemia Major

Identifiers

PMID40442554
PMCPMC12122548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.